Regenxbio Inc (NASDAQ:RGNX) — Market Cap & Net Worth
Market Cap & Net Worth: Regenxbio Inc (RGNX)
Regenxbio Inc (NASDAQ:RGNX) has a market capitalization of $404.48 Million ($404.48 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #13631 globally and #3106 in its home market, demonstrating a 1.45% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Regenxbio Inc's stock price $9.12 by its total outstanding shares 50623086 (50.62 Million). Analyse Regenxbio Inc cash conversion from operations to see how efficiently the company converts income to cash.
Regenxbio Inc Market Cap History: 2015 to 2026
Regenxbio Inc's market capitalization history from 2015 to 2026. Data shows change from $840.34 Million to $461.68 Million (-5.79% CAGR).
Index Memberships
Regenxbio Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.02% | #355 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1288 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.02% | #197 of 263 |
Weight: Regenxbio Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Regenxbio Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Regenxbio Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.70x
Regenxbio Inc's market cap is 4.70 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $840.34 Million | $7.59 Million | -$22.81 Million | 110.75x | N/A |
| 2016 | $939.06 Million | $4.59 Million | -$62.97 Million | 204.63x | N/A |
| 2017 | $1.68 Billion | $10.39 Million | -$73.17 Million | 161.96x | N/A |
| 2018 | $2.12 Billion | $218.50 Million | $99.94 Million | 9.72x | 21.25x |
| 2019 | $2.07 Billion | $35.23 Million | -$94.73 Million | 58.87x | N/A |
| 2020 | $2.30 Billion | $154.57 Million | -$111.25 Million | 14.86x | N/A |
| 2021 | $1.66 Billion | $470.35 Million | $127.84 Million | 3.52x | 12.95x |
| 2022 | $1.15 Billion | $112.72 Million | -$280.32 Million | 10.19x | N/A |
| 2023 | $908.68 Million | $90.24 Million | -$263.49 Million | 10.07x | N/A |
| 2024 | $391.32 Million | $83.33 Million | -$227.10 Million | 4.70x | N/A |
Competitor Companies of RGNX by Market Capitalization
Companies near Regenxbio Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Regenxbio Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Regenxbio Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Regenxbio Inc's market cap moved from $840.34 Million to $ 461.68 Million, with a yearly change of -5.79%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $461.68 Million | -36.67% |
| 2025 | $728.97 Million | +86.29% |
| 2024 | $391.32 Million | -56.94% |
| 2023 | $908.68 Million | -20.86% |
| 2022 | $1.15 Billion | -30.64% |
| 2021 | $1.66 Billion | -27.91% |
| 2020 | $2.30 Billion | +10.72% |
| 2019 | $2.07 Billion | -2.34% |
| 2018 | $2.12 Billion | +26.17% |
| 2017 | $1.68 Billion | +79.25% |
| 2016 | $939.06 Million | +11.75% |
| 2015 | $840.34 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Regenxbio Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $404.48 Million USD |
| MoneyControl | $404.48 Million USD |
| MarketWatch | $404.48 Million USD |
| marketcap.company | $404.48 Million USD |
| Reuters | $404.48 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Regenxbio Inc
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular … Read more